<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03108469</url>
  </required_header>
  <id_info>
    <org_study_id>15-001IS</org_study_id>
    <nct_id>NCT03108469</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of IONIS-PKKRx for Preventive Treatment of Chronic Migraine</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of ISIS 546254 for Preventive Treatment of Chronic Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Smith, Timothy R., M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinvest Research, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Smith, Timothy R., M.D.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and changes in the number
      of migraine and headache days with repeated subcutaneous administration of IONIS-PKKRx (ISIS
      546254) or placebo in subjects with chronic migraine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, placebo-controlled, randomized, multi-center study in subjects with
      chronic migraine. The study will consist of 7 office visits, 6 Sample collection visits and 3
      phone call assessments. Subjects agreeing to participate in the study and meeting the entry
      criteria assessed at the screening visit, will begin a 28 day baseline period to confirm
      their diagnosis, and establish a baseline frequency of migraine and headache days. During the
      baseline period, subjects will continue treating their migraines in their usual manner. They
      will monitor headache activity, migraine related symptoms, and medication usage with an
      electronic daily headache diary.

      Subjects who, after completing the baseline, continue to meet entrance criteria will be
      eligible to enter into the 4 month treatment phase. They will be randomized according to the
      Clinvest generated randomization schedule. A total of 30 randomized subjects will enter the
      treatment phase receiving IONIS-PKKRx (ISIS 546254; SC) or placebo in a 1:1 design. Study
      drug or placebo will be administered weekly for 16 weeks. A short phone call to assess any
      treatment related adverse events will take place 1 and 2 days after randomization. Daily
      electronic diary assessments will collect headache frequency and severity, associated
      migraine symptoms, acute medication usage, and the emergence of unusual symptoms and adverse
      events. Subjects will return to the site at weeks 4, 8, and 12 for investigational product
      (IP) accountability/dispensing, medication and medication updates, biomarker/lab sample
      collection, and assessment of adverse events. An end of treatment visit will take place 16
      weeks after randomization.

      Subjects will have a follow-up safety visit one month after their last dosage of IP ) for
      assessment of any adverse events (AE) and satisfaction and a final safety phone call 2 months
      following their last office visit (3 months after last dose of IP) for assessment of any
      adverse events (AE). Subjects will continue to complete headache diaries through Visit 7.
      Subjects will also have hematology samples collected every other week starting after Visit 2
      through Day 154.

      Safety and tolerability will be monitored by the Investigators. Patients who discontinue
      study treatment prematurely should complete any follow-up visits associated with the most
      recent dose and should move into and complete the Follow-up Phase.

      Subjects will undergo sampling for (pharmacokinetics) PK, coagulation, chemistry, hematology,
      and optional future biomedical research, as specified in the schedule of procedures.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Actual">April 26, 2019</completion_date>
  <primary_completion_date type="Actual">April 26, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>At randomization (Visit 2), neither the subject nor the investigator will be aware to which treatment group the subject has been assigned. Investigational product will be drawn and administered in a double blind format. If needed, for safety and proper treatment of the subject, the investigator can unblind the subject's treatment assignment to determine which treatment has been assigned and institute appropriate follow-up care. When possible, Sponsor and Clinvest should be notified prior to unblinding study drug.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Migraine Days</measure>
    <time_frame>Comparing baseline to treatment period, up to 16 weeks</time_frame>
    <description>Compare the efficacy of ISIS 546254 in the preventive treatment of chronic migraine, measured by the number of monthly migraine days comparing baseline to the final month of the 4-month treatment period for subjects treated with ISIS 546254 vs. placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Headache Severity</measure>
    <time_frame>Comparing baseline to treatment period, up to 16 weeks</time_frame>
    <description>Evaluate the efficacy of ISIS 546254 in the preventive treatment of chronic migraine, measured by the monthly headache severity comparing baseline to the final month of the 4-month treatment period for subjects treated with ISIS 546254 vs. placebo. Headache severity scale ranges from 1 (Mild) to 3 (Severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Headache Days</measure>
    <time_frame>Comparing baseline to treatment period, up to 16 weeks</time_frame>
    <description>Compare the efficacy of ISIS 546254 in the preventive treatment of chronic migraine, measured by the number of monthly headache days comparing baseline to the final month of the 4-month treatment period for subjects treated with ISIS 546254 vs. placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting a ≥ 50% Reduction in the Number of Migraine Headaches</measure>
    <time_frame>Comparing baseline to treatment period, up to 16 weeks</time_frame>
    <description>Compare the number of patients meeting 50% response criteria, response defined as a ≥ 50% reduction in the number of headaches from baseline to the final month of the 4-month treatment period for subjects treated with ISIS 546254 vs. placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count of Migraine Headache Days Requiring Use of Migraine Medication</measure>
    <time_frame>Comparing baseline to treatment period, up to 16 weeks</time_frame>
    <description>Compare the count of the number of headache days requiring use of medication for the treatment of migraine or headache pain (i.e., acute and rescue or breakthrough medication use) from baseline to the final month of the 4-month treatment period for subjects treated with ISIS 546254 vs. placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Migraine Specific Quality of Life (MSQ) Questionnaire Score</measure>
    <time_frame>Comparing baseline to treatment period, up to 16 weeks</time_frame>
    <description>Compare scores from baseline to the final month of the 4-month treatment period in the Migraine Specific Quality of Life (MSQ) Questionnaire for subjects treated with ISIS 546254 vs. placebo.
The MSQ total score is derived from the summation of fourteen questions on the MSQ. Answer options for the MSQ are coded as: 1 = None of the time, 2 = A little bit of the time, 3 = Some of the time, 4 = A good bit of the time, 5 = Most of the time, 6 = All of the time. The range of total MSQ score for each time point is 14 to 84, with higher scores indicating more effects of migraine on the subject's daily activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Global Impress of Change (PGIC) Score</measure>
    <time_frame>Evaluating the treatment period, but collected at the end of treatment, up to 16 weeks</time_frame>
    <description>Compare the end of treatment month 4 in the physician global impress of change (PGIC) for subjects treated with ISIS 546254 vs. placebo.
The PGIC is a one item questionnaire asking, &quot;Since the beginning of treatment in this study, how would you describe this patient's change (if any) in their overall status?&quot;. The answer option for the PGIC is coded as: 3 = Very Much Improved, 2 = Much Improved, 1 = Minimally Improved, 0 = No Change, -1 = Minimally Worse, -2 = Much Worse, -3 = Very Much Worse, with negative scores indicating the subject's overall status has decreased while in the study and positive scores indicating the subject's overall status has increased while in the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Global Impress of Change (SGIC) Score</measure>
    <time_frame>Evaluating the treatment period, but collected at the end of treatment, up to 16 weeks</time_frame>
    <description>Compare the end of treatment month 4 in the subjects' global impression of change (SGIC) for subjects treated with ISIS 546254 vs. placebo.
The SGIC is a one item questionnaire asking, &quot;Since the beginning of treatment in this study, how would you describe the change (if any) in your overall status?&quot;. The answer option for the SGIC is coded as: 3 = Very Much Improved, 2 = Much Improved, 1 = Minimally Improved, 0 = No Change, -1 = Minimally Worse, -2 = Much Worse, -3 = Very Much Worse, with negative scores indicating the subject's overall status has decreased while in the study and positive scores indicating the subject's overall status has increased while in the study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Chronic Migraine</condition>
  <arm_group>
    <arm_group_label>IONIS-PKKRx (ISIS 546254)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Those randomized to IONIS-PKKRx (ISIS 546254) will receive subcutaneous injections containing 1.00 mL (200mg) weekly for weeks 1-16.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Those randomized to placebo will receive subcutaneous injections containing 1.00 mL (200mg) weekly for weeks 1-16.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IONIS-PKKRx (ISIS 546254)</intervention_name>
    <description>Those randomized to IONIS-PKKRx (ISIS 546254) will receive subcutaneous injections containing 1.00 mL (200mg) of IONIS- PKKRx (ISIS 546254) weekly for weeks 1-16.</description>
    <arm_group_label>IONIS-PKKRx (ISIS 546254)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Those randomized to placebo will receive subcutaneous injections 1.00 mL (200mg) weekly for weeks 1-16.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Potential subjects must meet the following criteria at the screening visit to enter this
        study:

          1. male or female, in otherwise good health, 18 to 65 years of age.

          2. history of chronic migraine meeting the diagnostic criteria listed in the
             International Classification of Headache Disorders (ICHD-III beta version, 2013), as
             follows:

             a. History of frequent headaches suggestive of chronic migraine (15 or greater days of
             qualifying headaches per month) for at least three months prior to screening b.
             Verification of headache frequency through prospectively collected baseline
             information during the 28-day run-in phase demonstrating headaches on at least 15
             days, with at least 8 days per month fulfilling any ONE of the following; i. Qualify
             as being a migraine attack ii. Relieved by migraine specific acute medications

          3. onset of migraine before age 50.

          4. stable pattern of migraine pattern for at least 3 months prior to screening.

          5. not currently taking a migraine preventive OR has been taking a stable dose of a
             preventive for at least 30 days prior to screening and agrees to not start, stop, or
             change medication and/or dosage during the study period.

             i. Subjects on migraine preventative should have stable headache pattern ii.
             Injections of onabotulinumtoxinA are allowable if subject has completed at least 2
             injection cycles and agrees to maintain a regular injection cycle for the duration of
             the study

        Exclusion Criteria:

        Potential subjects meeting any of the following criteria will be excluded from entering
        this study:

          1. unable to understand the study requirements, the informed consent, or complete
             headache records as required per protocol.

          2. pregnant, actively trying to become pregnant, or breast-feeding.

          3. history of medication overuse (MO) of opioids, or butalbital, as defined by ICHD-3
             beta criteria and/or MO during baseline period.

          4. history of substance abuse and/or dependence, in the opinion of the Investigator.

          5. unstable neurological condition or a significantly abnormal neurological examination
             with focal signs or signs of increased intracranial pressure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy R Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinvest Research, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>StudyMetrix</name>
      <address>
        <city>Saint Peters</city>
        <state>Missouri</state>
        <zip>63303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinvest Research, LLC</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 27, 2017</study_first_submitted>
  <study_first_submitted_qc>April 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2017</study_first_posted>
  <results_first_submitted>January 20, 2020</results_first_submitted>
  <results_first_submitted_qc>January 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 5, 2020</results_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Smith, Timothy R., M.D.</investigator_affiliation>
    <investigator_full_name>Timothy Smith</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>migraine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 12, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/69/NCT03108469/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 17, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/69/NCT03108469/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>IONIS-PKKRx (ISIS 546254)</title>
          <description>Those randomized to IONIS-PKKRx (ISIS 546254) received subcutaneous injections containing 1.00 mL (200mg/mL) weekly for weeks 1-16.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Those randomized to placebo will receive subcutaneous injections containing 1.00 mL weekly for weeks 1-16.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IONIS-PKKRx (ISIS 546254)</title>
          <description>Those randomized to IONIS-PKKRx (ISIS 546254) received subcutaneous injections containing 1.00 mL (200mg/mL) weekly for weeks 1-16.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Those randomized to placebo will receive subcutaneous injections containing 1.00 mL weekly for weeks 1-16.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.6" spread="13.04"/>
                    <measurement group_id="B2" value="38.4" spread="10.83"/>
                    <measurement group_id="B3" value="37.16" spread="12.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Migraine Days</title>
        <description>Compare the efficacy of ISIS 546254 in the preventive treatment of chronic migraine, measured by the number of monthly migraine days comparing baseline to the final month of the 4-month treatment period for subjects treated with ISIS 546254 vs. placebo.</description>
        <time_frame>Comparing baseline to treatment period, up to 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IONIS-PKKRx (ISIS 546254)</title>
            <description>Those randomized to IONIS-PKKRx (ISIS 546254) received subcutaneous injections containing 1.00 mL (200mg/mL) weekly for weeks 1-16.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Those randomized to placebo will receive subcutaneous injections containing 1.00 mL weekly for weeks 1-16.</description>
          </group>
        </group_list>
        <measure>
          <title>Migraine Days</title>
          <description>Compare the efficacy of ISIS 546254 in the preventive treatment of chronic migraine, measured by the number of monthly migraine days comparing baseline to the final month of the 4-month treatment period for subjects treated with ISIS 546254 vs. placebo.</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.267" spread="1.48"/>
                    <measurement group_id="O2" value="14.133" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.067" spread="2.08"/>
                    <measurement group_id="O2" value="9.867" spread="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Headache Severity</title>
        <description>Evaluate the efficacy of ISIS 546254 in the preventive treatment of chronic migraine, measured by the monthly headache severity comparing baseline to the final month of the 4-month treatment period for subjects treated with ISIS 546254 vs. placebo. Headache severity scale ranges from 1 (Mild) to 3 (Severe).</description>
        <time_frame>Comparing baseline to treatment period, up to 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IONIS-PKKRx (ISIS 546254)</title>
            <description>Those randomized to IONIS-PKKRx (ISIS 546254) received subcutaneous injections containing 1.00 mL (200mg/mL) weekly for weeks 1-16.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Those randomized to placebo will receive subcutaneous injections containing 1.00 mL weekly for weeks 1-16.</description>
          </group>
        </group_list>
        <measure>
          <title>Headache Severity</title>
          <description>Evaluate the efficacy of ISIS 546254 in the preventive treatment of chronic migraine, measured by the monthly headache severity comparing baseline to the final month of the 4-month treatment period for subjects treated with ISIS 546254 vs. placebo. Headache severity scale ranges from 1 (Mild) to 3 (Severe).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.605" spread="0.106"/>
                    <measurement group_id="O2" value="1.538" spread="0.084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.202" spread="0.146"/>
                    <measurement group_id="O2" value="0.994" spread="0.170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Headache Days</title>
        <description>Compare the efficacy of ISIS 546254 in the preventive treatment of chronic migraine, measured by the number of monthly headache days comparing baseline to the final month of the 4-month treatment period for subjects treated with ISIS 546254 vs. placebo.</description>
        <time_frame>Comparing baseline to treatment period, up to 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IONIS-PKKRx (ISIS 546254)</title>
            <description>Those randomized to IONIS-PKKRx (ISIS 546254) received subcutaneous injections containing 1.00 mL (200mg/mL) weekly for weeks 1-16.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Those randomized to placebo will receive subcutaneous injections containing 1.00 mL weekly for weeks 1-16.</description>
          </group>
        </group_list>
        <measure>
          <title>Headache Days</title>
          <description>Compare the efficacy of ISIS 546254 in the preventive treatment of chronic migraine, measured by the number of monthly headache days comparing baseline to the final month of the 4-month treatment period for subjects treated with ISIS 546254 vs. placebo.</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.267" spread="1.27"/>
                    <measurement group_id="O2" value="23.733" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.733" spread="2.11"/>
                    <measurement group_id="O2" value="14.333" spread="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting a ≥ 50% Reduction in the Number of Migraine Headaches</title>
        <description>Compare the number of patients meeting 50% response criteria, response defined as a ≥ 50% reduction in the number of headaches from baseline to the final month of the 4-month treatment period for subjects treated with ISIS 546254 vs. placebo.</description>
        <time_frame>Comparing baseline to treatment period, up to 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IONIS-PKKRx (ISIS 546254)</title>
            <description>Those randomized to IONIS-PKKRx (ISIS 546254) received subcutaneous injections containing 1.00 mL (200mg/mL) weekly for weeks 1-16.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Those randomized to placebo will receive subcutaneous injections containing 1.00 mL weekly for weeks 1-16.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting a ≥ 50% Reduction in the Number of Migraine Headaches</title>
          <description>Compare the number of patients meeting 50% response criteria, response defined as a ≥ 50% reduction in the number of headaches from baseline to the final month of the 4-month treatment period for subjects treated with ISIS 546254 vs. placebo.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Count of Migraine Headache Days Requiring Use of Migraine Medication</title>
        <description>Compare the count of the number of headache days requiring use of medication for the treatment of migraine or headache pain (i.e., acute and rescue or breakthrough medication use) from baseline to the final month of the 4-month treatment period for subjects treated with ISIS 546254 vs. placebo.</description>
        <time_frame>Comparing baseline to treatment period, up to 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IONIS-PKKRx (ISIS 546254)</title>
            <description>Those randomized to IONIS-PKKRx (ISIS 546254) received subcutaneous injections containing 1.00 mL (200mg/mL) weekly for weeks 1-16.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Those randomized to placebo will receive subcutaneous injections containing 1.00 mL weekly for weeks 1-16.</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Migraine Headache Days Requiring Use of Migraine Medication</title>
          <description>Compare the count of the number of headache days requiring use of medication for the treatment of migraine or headache pain (i.e., acute and rescue or breakthrough medication use) from baseline to the final month of the 4-month treatment period for subjects treated with ISIS 546254 vs. placebo.</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="1.64"/>
                    <measurement group_id="O2" value="14.733" spread="2.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.733" spread="1.64"/>
                    <measurement group_id="O2" value="7.733" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Migraine Specific Quality of Life (MSQ) Questionnaire Score</title>
        <description>Compare scores from baseline to the final month of the 4-month treatment period in the Migraine Specific Quality of Life (MSQ) Questionnaire for subjects treated with ISIS 546254 vs. placebo.
The MSQ total score is derived from the summation of fourteen questions on the MSQ. Answer options for the MSQ are coded as: 1 = None of the time, 2 = A little bit of the time, 3 = Some of the time, 4 = A good bit of the time, 5 = Most of the time, 6 = All of the time. The range of total MSQ score for each time point is 14 to 84, with higher scores indicating more effects of migraine on the subject's daily activities.</description>
        <time_frame>Comparing baseline to treatment period, up to 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IONIS-PKKRx (ISIS 546254)</title>
            <description>Those randomized to IONIS-PKKRx (ISIS 546254) received subcutaneous injections containing 1.00 mL (200mg/mL) weekly for weeks 1-16.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Those randomized to placebo will receive subcutaneous injections containing 1.00 mL weekly for weeks 1-16.</description>
          </group>
        </group_list>
        <measure>
          <title>Migraine Specific Quality of Life (MSQ) Questionnaire Score</title>
          <description>Compare scores from baseline to the final month of the 4-month treatment period in the Migraine Specific Quality of Life (MSQ) Questionnaire for subjects treated with ISIS 546254 vs. placebo.
The MSQ total score is derived from the summation of fourteen questions on the MSQ. Answer options for the MSQ are coded as: 1 = None of the time, 2 = A little bit of the time, 3 = Some of the time, 4 = A good bit of the time, 5 = Most of the time, 6 = All of the time. The range of total MSQ score for each time point is 14 to 84, with higher scores indicating more effects of migraine on the subject's daily activities.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.133" spread="2.40"/>
                    <measurement group_id="O2" value="50.133" spread="2.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.133" spread="3.46"/>
                    <measurement group_id="O2" value="40.733" spread="3.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician Global Impress of Change (PGIC) Score</title>
        <description>Compare the end of treatment month 4 in the physician global impress of change (PGIC) for subjects treated with ISIS 546254 vs. placebo.
The PGIC is a one item questionnaire asking, &quot;Since the beginning of treatment in this study, how would you describe this patient's change (if any) in their overall status?&quot;. The answer option for the PGIC is coded as: 3 = Very Much Improved, 2 = Much Improved, 1 = Minimally Improved, 0 = No Change, -1 = Minimally Worse, -2 = Much Worse, -3 = Very Much Worse, with negative scores indicating the subject's overall status has decreased while in the study and positive scores indicating the subject's overall status has increased while in the study.</description>
        <time_frame>Evaluating the treatment period, but collected at the end of treatment, up to 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IONIS-PKKRx (ISIS 546254)</title>
            <description>Those randomized to IONIS-PKKRx (ISIS 546254) received subcutaneous injections containing 1.00 mL (200mg/mL) weekly for weeks 1-16.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Those randomized to placebo will receive subcutaneous injections containing 1.00 mL weekly for weeks 1-16.</description>
          </group>
        </group_list>
        <measure>
          <title>Physician Global Impress of Change (PGIC) Score</title>
          <description>Compare the end of treatment month 4 in the physician global impress of change (PGIC) for subjects treated with ISIS 546254 vs. placebo.
The PGIC is a one item questionnaire asking, &quot;Since the beginning of treatment in this study, how would you describe this patient's change (if any) in their overall status?&quot;. The answer option for the PGIC is coded as: 3 = Very Much Improved, 2 = Much Improved, 1 = Minimally Improved, 0 = No Change, -1 = Minimally Worse, -2 = Much Worse, -3 = Very Much Worse, with negative scores indicating the subject's overall status has decreased while in the study and positive scores indicating the subject's overall status has increased while in the study.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.867" spread="0.215"/>
                    <measurement group_id="O2" value="1.00" spread="0.258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Global Impress of Change (SGIC) Score</title>
        <description>Compare the end of treatment month 4 in the subjects' global impression of change (SGIC) for subjects treated with ISIS 546254 vs. placebo.
The SGIC is a one item questionnaire asking, &quot;Since the beginning of treatment in this study, how would you describe the change (if any) in your overall status?&quot;. The answer option for the SGIC is coded as: 3 = Very Much Improved, 2 = Much Improved, 1 = Minimally Improved, 0 = No Change, -1 = Minimally Worse, -2 = Much Worse, -3 = Very Much Worse, with negative scores indicating the subject's overall status has decreased while in the study and positive scores indicating the subject's overall status has increased while in the study.</description>
        <time_frame>Evaluating the treatment period, but collected at the end of treatment, up to 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IONIS-PKKRx (ISIS 546254)</title>
            <description>Those randomized to IONIS-PKKRx (ISIS 546254) received subcutaneous injections containing 1.00 mL (200mg/mL) weekly for weeks 1-16.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Those randomized to placebo will receive subcutaneous injections containing 1.00 mL weekly for weeks 1-16.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Global Impress of Change (SGIC) Score</title>
          <description>Compare the end of treatment month 4 in the subjects' global impression of change (SGIC) for subjects treated with ISIS 546254 vs. placebo.
The SGIC is a one item questionnaire asking, &quot;Since the beginning of treatment in this study, how would you describe the change (if any) in your overall status?&quot;. The answer option for the SGIC is coded as: 3 = Very Much Improved, 2 = Much Improved, 1 = Minimally Improved, 0 = No Change, -1 = Minimally Worse, -2 = Much Worse, -3 = Very Much Worse, with negative scores indicating the subject's overall status has decreased while in the study and positive scores indicating the subject's overall status has increased while in the study.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.867" spread="0.291"/>
                    <measurement group_id="O2" value="1.13" spread="0.350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>196 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>IONIS-PKKRx (ISIS 546254)</title>
          <description>Those randomized to IONIS-PKKRx (ISIS 546254) received subcutaneous injections containing 1.00 mL (200mg/mL) weekly for weeks 1-16.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Those randomized to placebo will receive subcutaneous injections containing 1.00 mL weekly for weeks 1-16.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Gastrectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="96" subjects_affected="15" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="31" subjects_affected="9" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="51" subjects_affected="11" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="23" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jim Sly</name_or_title>
      <organization>Clinvest Research</organization>
      <phone>4178413673</phone>
      <email>jsly@clinvest.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

